BridgeBio Pharma Inc (NASDAQ: BBIO) shares gained 1.89%, or $0.87 per share, to close Friday at $47.00. After opening the day at $46.13, shares of BridgeBio Pharma fluctuated between $47.02 and $45.33. 504,891 shares traded hands a decrease from their 30 day average of 821,093. Friday’s activity brought BridgeBio Pharma’s market cap to $7,038,974,458.
BridgeBio Pharma is headquartered in Palo Alto, California..
About BridgeBio Pharma Inc
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
Visit BridgeBio Pharma Inc’s profile for more information.
The Daily Fix
Here’s a trending selection from our newsletter, The Daily Fix, that captured readers’ attention. Click here to subscribe and get The Daily Fix delivered right to your inbox.
McDonald’s To Offer New Plant-Based Burger in US Restaurants by Beyond Meat
Starting Nov. 3, the “McPlant” will be on the menu at eight locations in Texas, Louisiana, Iowa and California as part of a trial run to help gauge customer interest in the meatless offering, McDonald’s announced last week.
Breaking the Supply Chain Bottleneck
Since the start of the global pandemic, historically low interest rates and government spending have inhibited saving and encouraged borrowing and spending to lift the economy during the challenging period. The US Federal Reserve and government have pumped far more liquidity into the financial system than during the 2008 global financial crisis. We have seen an increase in inflationary pressures because of the stimulus. Moreover, the pandemic’s unintended consequences have created shortages and supply chain bottlenecks that have only exacerbated rising prices.
How Entrepreneurs Can Build and Maintain Successful Venture Capital and Private Equity Relationships
The first three quarters of 2021 have brought ample opportunity for startups and small businesses seeking capital investments. According to a report from PitchBook, overall venture capital funding in the U.S. hit a new record of $238.7 billion raised in the first nine months of the year, crushing the previous annual record of $166.4 billion that was raised in all of 2020. Early-stage capital alone has exceeded $54 billion through Sept. 30, beating last year’s record volume of $44 billion.
With more opportunity, however, comes more competition. Entrepreneurs who have decided to seek venture capital or private equity investment will need to stand out. Strategizing around getting and keeping investor attention early on can help.
About The Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world’s leading exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information on BridgeBio Pharma Inc and to follow the company’s latest updates, you can visit the company’s profile page here: BridgeBio Pharma Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer